CD24 and carcinoma: While the EMT/MET genetic program has yet to be fully understood in cancer, recent studies showed that upregulation of two novel EMT key markers, CD44 and CD24, are necessary for entry into a mesenchymal-like state in highly drug resistant breast HER2 positive carcinoma[25].